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1. Introduction 
Sarcoidosis is a granulomatous, inflammatory disease that can affect multiple systems of the 
body. Most commonly this involves the lungs, skin, and eyes, but also can affect the nervous 
system in about 5% of cases (Delaney1977, Stern et al 1985). Neurological sarcoidosis may be 
associated with virtually any aspect of the nervous system, but just like the predilection for 
certain organ systems in systemic disease, neurological involvement also may demonstrate 
characteristic clinical patterns to aid in the recognition of the disorder. This is especially 
important because the presenting manifestations may be neurological in nearly 50% of these 
patients (Stern et al 1985). The first large review of the trends of clinical involvement of the 
nervous system in sarcoidosis was outlined over 60 years ago (Colover 1948). Subsequent 
reviews and case reports have built on that foundation. This chapter will outline the clinical 
manifestations, diagnostic considerations, and management options, including new trends 
in therapy of neurological sarcoidosis. 
2. Clinical manifestations 
The most classic clinical patterns of nervous system involvement in sarcoidosis include 
cranial neuropathy, meningeal based disease, and hypothalamic-pituitary axis 
symptomatology. Cranial neuropathy is the most common neurological deficit with an 
incidence of 50 to 75% of patients (Delaney 1977, Stern et al 1985). In general, meningeal 
based disease is a common hallmark of neurosarcoidosis and can manifest in a variety of 
ways as outlined below. Hypothalamic-pituitary axis involvement may yield only relatively 
nonspecific symptomatology, but can be a frequent and important manifestation, as well. 
The most common cranial neuropathy is a facial palsy. In hindsight, the first historically 
described cases occurred early in the 20th century, when unusual presentations of parotid 
enlargement, uveitis, and facial palsies were described (Heerfordt 1909). Years later facial 
palsy was documented in half of neurosarcoidosis patients (Colover 1948, Stern et al 1985), 
making it the most predominant clinical association. A third of these cases are bilateral 
(Colover 1948, Stern et al 1985), and those presentations or recurrent facial palsy in general 
should trigger a suspicion for a secondary cause of facial palsy, such as Lyme disease or 
neurosarcoidosis. 
The second most common cranial neuropathy is of the optic nerve. The incidence of this 
presenting complaint is rather high, and actually in more recent papers, some have 
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described this as being even more common than facial palsy (Pawate et al 2009, Joseph and 
Scolding 2009). Referral bias was considered as a cause of this as Pawate’s data came from a 
multiple sclerosis center, whereas Stern’s prior data noted above came from a sarcoidosis 
clinic. Regardless, sarcoidosis needs to be in the differential of secondary causes of optic 
neuritis within the appropriate clinical context, and bilateral optic neuritis, in particular, 
may herald an even stronger neurological suspicion for sarcoidosis, along with other 
conditions that may classically present that way, such as neuromyelitis optica.  
Unfortunately, bilateral optic neuritis tends to have a markedly worse prognosis for 
recovery compared to unilateral optic neuritis (Pawate et al 2009).  Of note, it is important to 
keep in mind that the most common ocular symptoms in sarcoidosis are still primary 
ophthalmological manifestations, such as uveitis.  
The eighth cranial nerve is affected in up to one fifth of patients. This involvement tends to 
be bilateral, and appears to be related to granulomatous meningitis in most cases. Patients 
may experience hearing loss or have vestibular dysfunction. This may present suddenly or 
with a fluctuating course. Recovery of function is less common than with facial palsies. 
(Stern et al 1985) The most common extraocular muscle palsy is of the sixth nerve (Joseph 
and Scolding 2009). Trigeminal neuropathies have also been well described in association 
with sarcoidosis (Armin A and Balderacchi JL 2010).  Cranial nerve nine and ten palsies may 
result in dysphagia, hoarseness, or vocal cord paralysis (Delaney 1977). Though an ENT 
study documented neurosarcoidosis of the vagus nerve to be rare in their general patient 
population, they noted it should still be considered in the differential diagnosis of vocal cord 
paresis or paralysis (Alon and Ekbom 2010). Although felt to be uncommon, decreased smell 
might be an underreported complication given that the 1st cranial nerve is not commonly 
tested on examination. Significant, symptomatic anosmia from sarcoidosis is more 
commonly encountered in patients with significant generalized disease and it can be 
refractory to treatment (Aubart et al 2006). Essentially, any cranial nerve may be affected by 
the granulomatous infiltration of sarcoidosis, though the rest of the cranial nerves not 
outlined above would only very rarely be involved. 
Meningeal based disease is another classic finding of neurosarcoidosis. In fact this 
meningeal based disease is also not only responsible for many of the cranial neuropathic 
complications, but presents in a variety of other ways, as well.  Significant basilar disease 
can be associated with a polycranial neuropathy from meningeal infiltration. Meningeal 
disease may cause headache related to acute aseptic or chronic meningitis.  In one large 
review series at the Mayo Clinic, chronic meningitis was actually the most common initial 
manifestation of neurosarcoidosis (Aksamit and Norona 1999). If cerebrospinal fluid flow 
becomes obstructed, then headache might also be a manifestation of hydrocephalus.  
Weakness, pain, and sensory dysfunction can be seen in some cases with polyradicular 
involvement from spinal meningeal infiltration. All together, some form of meningeal 
involvement is a very common and suggestive feature of neurological sarcoidosis. 
Hypothalamic-pituitary axis symptomatology can be rather nonspecific, but taken into 
context with other features of neurosarcoidosis, it might help tip the balance of clinical 
evidence to proceed further with testing for sarcoidosis. Diabetes insipidus is considered the 
most common manifestation, accounting for half of all neuroendocrine abnormalities 
(Chapelon et al 1990). Of note, an organic primary polydipsia may also be the cause of 
polyuria and polydipsia, and hypercalcemia from sarcoidosis can cause nephrogenic 
diabetes insipidus (Stuart et al 1980). Other relatively common neuroendocrine 
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manifestations of sarcoidosis include amenorrhea or galactorrhea. Serum prolactin levels 
have been high in up to a third of patients in general with sarcoidosis (Turkington and 
Macindoe JH 1972), and that unexpected high percentage could reflect that some degree of 
subclinical neurological involvement is associated with many more systemic sarcoidosis 
patients than previously thought. A more complete list of possible endocrine manifestations 
of sarcoidosis includes morbid obesity, dysregulation of body temperature, insomnia, 
personality change, SIADH, diabetes insipidus, hyperprolactinemia, hypothyroidism, 
hypoadrenalism, growth hormone deficiency, and impaired counter-regulatory response to 
hypoglycemia (Porter et al 2003). 
In addition to the above classical neurological manifestations of sarcoidosis, there are 
several other neurological entities that are seen with intermediate frequency and less 
specificity. This may include seizures, which have been reported in 10% to 17% of patients 
(Delaney 1977, Pawate et al 2009, Joseph and Scolding 2009). Seizures correlate with a worse 
prognosis overall, likely as a reflection of more significant underlying parenchymal disease. 
In addition to seizures, central nervous system granulomatous mass lesions can cause 
headache, lethargy, or other localization related symptomatology. (Stern et al 1985) Spinal 
cord disease also can present with intermediate frequency. Leptomeningeal infiltration in 
the region of the spinal cord is associated with sarcoidosis, but intraparenchymal infiltration 
can occur, too, causing fusiform spinal cord enlargement, focal or diffuse intramedullary 
disease, or spinal cord atrophy (Junger et al 1993). Based on recent reports, greater than 15% 
of initial clinical presentations of neurosarcoidosis can be related to myelopathy or spinal 
cord disease in general (Pawate et al 2009, Joseph and Scolding 2009). A longitudinal 
myelitis can be the presenting symptom of neurosarcoidosis, making this a consideration 
with other longitudinally extensive cord inflammatory syndromes (Sierra-Hidalgo et al 
2010), such as neuromyelitis optica or connective tissue disorders such as Sjogren's disease 
or Lupus. Neuropsychiatric disorders also have an intermediate incidence. The 
symptomatology related to this can include encephalopathy, psychosis, depression, bipolar 
disorder, apathy, irritability, and lethargy (Joseph and Scolding 2007, De Mulder and 
Vandenberghe 2008, Spiegel et al 2010, Friedman and Gould 2002, Bona et al 1998, O’Brien 
et al 1994, Sabaawi et al 1992). One should consider these neuropsychiatric symptoms to 
potentially be organic and possibly responsive to immunomodulatory therapy rather than 
just primary psychological causes. Interestingly, a patient has been described as having 
abnormal cerebrospinal fluid with isolated psychiatric symptoms (Gilmore et al 1980).  
Peripheral nervous system involvement occurs in about 15% of neurosarcoidosis cases and 
typically has a better prognosis than central nervous system involvement (Delaney 1977). A 
subacute generalized axonal sensorimotor polyneuropathy is the typical subtype of 
polyneuropathy seen in sarcoidosis (Zuniga et al 1991), but one must take into account that 
asymmetrical peripheral neuropathic limb symptomatology can be seen with 
polyradiculoneuropathy, which is a very well documented presentation in this disorder 
(Burns et al 2006).  Sarcoidosis can also cause mononeuropathy with a notable increased 
incidence of carpal tunnel syndrome (Niemer et al 2001) among other mononeuropathy 
presentations.  A more diffuse mononeuritis multiplex picture may occur (Zuniga et al 1999, 
Garg et al 2005), purely sensory neuropathy may be seen, and even rare associations of 
lumbosacral plexopathy have been encountered (Zuniga et al 1991).  Small fiber neuropathy 
needs to be considered in sarcoidosis, as well (Tavee and Culver 2011, Hoitsma et al 2002).  
Finally, there have even been reports of Guillain-Barre like illnesses associated with 
neurosarcoidosis (Fahoum et al 2009).  
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Muscle involvement symptomatically ranges from less than 1% to potentially up to 26% of 
patients (Oksanen 1986, Chapelon et al 1990). Symmetrical myopathic weakness or 
myalgias can be experienced. There may be isolated palpable nodules within the muscle.  
More often, though, muscle involvement is asymptomatic. This asymptomatic 
involvement can be seen in up to 50% of muscle biopsies (Delaney 1977). Vascular 
infiltration is remarkably rare, with a very low incidence of hemorrhage or stroke. 
Movement disorders other than cerebellar ataxia are very rare, with only isolated reports 
of extrapyramidal symptoms from basal ganglia involvement, such as chorea, 
hemiballism, and Parkinsonism (Delaney 1977).  
To summarize, the classical clinical findings include cranial neuropathy, meningeal based 
disease, and hypothalamic-pituitary axis symptomatology. Intermediate frequency 
symptomatology, such as seizures, spinal cord disease, peripheral neuropathy, muscle 
disease, or neuropsychiatric manifestations can be rather non-specific. Early recognition of 
systemic signs and symptoms of ocular disease, lung disease, and skin disease increases the 
yield of recognizing the disorder.  In addition, 30% of patients present with more than one 
neurological manifestation (Stern et al 1985), which may increase the clinical context for 
suspecting the diagnosis, even in cases without systemic disease. As there is no gold 
standard test, except for biopsy, clinical acumen is necessary to combine clinical suspicion 
with optimal understanding of non-invasive test strategies to select appropriate patients 
without a known diagnosis of sarcoidosis for pathological tissue studies to confirm the 
diagnosis.  The next section will expand upon diagnostic considerations. 
 
Classical features 
Cranial neuropathy 
Meningeal based disease 
Hypothalamic-pituitary axis dysfunction 
 
Intermediate frequency features 
Seizures 
Encephalopathy/psychiatric symptomatology 
Spinal cord disease 
Peripheral neuropathy 
Table 1. Major clinical features of neurosarcoidosis 
 
Most common cranial neuropathies in sarcoidosis in order of frequency 
Bell’s palsy (Cranial Nerve 7) 
Optic neuropathy/neuritis (Cranial Nerve 2) 
Vestibulocochlear neuropathy (Cranial Nerve 8) 
 
Other cranial nerves with intermediate frequency 
Cranial Nerves 5, 6, 9, or 10 
Table 2. Cranial nerve involvement in sarcoidosis 
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3. Diagnostic considerations 
Once neurosarcoidosis is considered in the differential diagnosis, the next step is to 
further evaluate this with non-invasive supportive diagnostic testing. MRI with contrast, 
lumbar puncture, and ACE levels should all be considered in the initial work-up, though 
these tests lack specificity.  In cases without systemic involvement, routine chest imaging 
should be undertaken at a minimum, and further supportive testing such as gallium 
scanning or bronchoalveolar lavage should also be considered. Nevertheless, pathological 
confirmation of tissue, demonstrating non-caseating granulomas, is necessary to justify 
treatment for this disorder. The proposed criteria for the diagnosis of neurosarcoidosis 
has been partitioned into definite, probable, or possible disease (Zajicek et al 1999). 
Definite disease consists of a clinical presentation compatible with neurosarcoidosis, 
exclusion of other possible causes, and confirmation with biopsy of nervous system tissue, 
such as the meninges or another source. Probable disease is defined as a clinical 
presentation compatible with neurosarcoidosis, non-invasive neurodiagnostic support of 
the diagnosis, exclusion of other possible causes, and evidence of systemic sarcoidosis by 
biopsy. Possible neurosarcoidosis is defined as a clinical presentation compatible with 
neurosarcoidosis clinically and with noninvasive neurodiagnostic studies, along with 
exclusion of other possible causes.  
Developing a focused differential diagnosis based on the site of neurological involvement 
is critical to effectively excluding other disorders that may mimic neurosarcoidosis. 
Classical disease that involves a meningeal process would require the exclusion of 
infectious and malignant etiologies. Examples of this would range from chronic infectious 
processes, such as fungal infections and tuberculosis to malignant processes such as 
carcinomatous or lymphomatous meningitis. These would all be highly pertinent 
considerations in patients with basilar infiltration causing polycranial neuropathies. 
Restricted cranial nerve lesions, such as unilateral Bell's palsy may be clinically 
indistinguishable from idiopathic cases, though recurrent or bilateral disease should 
invoke consideration of secondary causes such as sarcoidosis, Lyme disease, or a rare 
disorder, Melkersson-Rosenthal syndrome. Similarly, unilateral optic neuritis might 
suggest multiple sclerosis in the differential, whereas bilateral disease increases the 
suspicion of sarcoidosis or other disorders, such as neuromyelitis optica. Transverse 
myelitis might be difficult to distinguish from idiopathic demyelination or multiple 
sclerosis, but longitudinally extensive lesions, which can be seen in neurosarcoidosis, 
bring several diagnostic considerations to the forefront, such as neuromyelitis optica, 
connective tissue disorders such as Sjogren's or Lupus, or vascular disorders, such as 
dural A-V fistula. White matter disease on MRI would necessitate differentiation from 
multiple sclerosis, nonspecific vascular disease, inflammatory/vasculitic etiologies, or 
infectious considerations like Lyme disease. HIV can masquerade as having many of the 
features of neurosarcoidosis, in general. Multi-systemic disease may suggest other 
uncommon syndromes, such as amyloidosis. Mass lesions in the brain from sarcoid 
granulomas need differentiation from other lesions such as tumor or abscess. Dural 
lesions can mimic meningioma. A vasculopathy appearance with encephalopathy must be 
differentiated from CNS vasculitis or neurosyphilis. Finally, peripheral nervous system 
involvement is much more nonspecific. With peripheral neuropathic processes, the 
differential diagnosis depends on the location, neurophysiology, and timing of the 
neuropathy. For instance, the most common polyneuropathy of an axonal sensorimotor 
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polyneuropathy might be difficult to distinguish from the common causes of metabolic 
polyneuropathy, such as diabetes, thyroid disease, vitamin deficiency, connective tissue 
disease, toxins, or monoclonal gammopathies associated with or without significant 
underlying hematological disease. A subacute onset might help lean more towards an 
acquired, inflammatory cause in the differential, though.  With a mononeuritis multiplex 
picture, one would need to differentiate between vasculitis, diabetes, or less common 
infectious etiologies such as hepatitis, Lyme, or HIV.  Isolated mononeuropathy would be 
difficult to distinguish from common entrapment neuropathies.  As mentioned above, an 
acute polyneuropathy with a Guillain-Barre phenotype can be seen.  A Guillain-Barre like 
illness with unexpected cerebrospinal fluid pleocytosis (Fahoum et al 2009) in addition to 
the expected high protein level might signal other considerations like HIV or sarcoidosis 
as underlying etiologies. 
Compatible epidemiological features such as younger patients and an African American 
predominance can be clues, though very non-specific given the differential diagnosis above.  
In cases of known systemic sarcoidosis, the diagnosis mainly entails ruling out other 
etiologies of neurological involvement, especially infectious causes given these patients may 
already be immunosuppressed.  In cases without systemic involvement, the diagnosis can 
be challenging and further experience with the details of the diagnostic workup is necessary. 
We will discuss the noninvasive diagnostic strategies first. This will include MRI studies 
with contrast, cerebral spinal fluid studies, ACE levels, chest imaging, and gallium studies.  
Analyzing five large case reviews (Zajicek et al 1999, Christoforidis et al 1999, Aksamit and 
Norona 1999, Pawate et al 2009, Joseph and Scolding 2009), the following trends and details 
regarding specific diagnostic tests emerge. 
MRI of the brain with contrast, as well as the spinal cord, if symptomatology and exam 
findings suggest localization there, is a key to the diagnostic workup.  The sensitivity rate 
for an abnormal brain MRI with contrast in patients with symptoms referable to the central 
nervous system may be as high as 80 to 90% (Christoforidis et al 1999, Pawate et al 2009).  
Overall, spinal cord abnormalities are seen in 10-20% of cases (Zajicek et al 1999, Pawate et 
al 2009).  However, when spinal cord symptomatology is present, imaging is abnormal in 
roughly 60-70% of cases (Aksamit and Norona 1999, Pawate et al 2009). 
On MRI of the brain, nonspecific white matter lesions are common, with roughly 40% of 
cases showing these findings (Zajicek et al 1999).  Patients with isolated white matter disease 
tend to have a good prognosis.  Nevertheless, this is a very nonspecific finding and a 
contrast enhanced study with gadolinium will demonstrate much more of the classical 
features of sarcoidosis.  Meningeal enhancement is quite common and can be seen in nearly 
40% of cases (Zajicek et al 1999).  There are multiple other enhancing abnormalities that can 
be encountered, too. Strictly dural enhancement may be seen, as well as isolated cranial 
nerve enhancement, focal parenchymal enhancement associated with a white matter lesion 
or with a focal mass (in general parenchymal enhancement has a relative predilection for the 
hypothalamic-pituitary axis), or periventricular radial vascular enhancement.  In 10-15% of 
neurosarcoidosis patients, hydrocephalus can be present (Zajicek et al 1999). Vasculitic 
infarcts are very rare, but do occur (Pawate et al 2009).  Interestingly, 40% of cranial nerve 
deficits were not associated with their respective cranial nerves having enhancement on 
MRI, though conversely 44% of patients had MRI evidence of cranial nerve involvement 
with no symptoms related to that radiologically affected site (Christoforidis et al 1999).  The 
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findings of Christoforidis also noted that even though hypothalamic-pituitary axis 
enhancement is not a rare finding on imaging, 50% of patients with symptoms related to the 
hypothalamic-pituitary axis had no abnormal findings on imaging in that region. Spinal 
cord lesions most typically consist of meningeal enhancement, spinal cord swelling, or 
enhancing myelitis of the cord (Pawate 2009). 
 
Common MRI Brain features of neurosarcoidosis 
Non specific white matter changes 
Meningeal thickening/enhancement 
Cranial nerve enhancement 
Parenchymal enhancement of white matter lesion or a focal mass 
Parenchymal enhancement has a relatively greater predilection for the hypothalamic-
pituitary axis 
Hydrocephalus 
 
MRI Spine features of neurosarcoidosis 
Meningeal or radicular enhancement/thickening 
Cord swelling 
Myelitis (often enhancing) 
Table 3. Imaging findings in neurological sarcoidosis 
 
 
Fig. 1. Gadolinium enhanced MRI of the brain demonstrating basilar leptomeningeal 
enhancement and hydrocephalus 
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Fig. 2. Gadolinium enhanced MRI of the brain demonstrating bilateral optic nerve and 
pituitary axis enhancement 
 
 
 
Fig. 3. MRI of the lumbosacral spine demonstrating diffuse radicular nodularity 
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Fig. 4. Gadolinium enhanced MRI of the thoracic spine demonstrating scattered nodular 
enhancement. 
Spinal fluid evaluation is indicated for all patients suspected of having neurosarcoidosis, 
assuming that there is not a risk for herniation based on CNS imaging.  Cerebrospinal fluid 
evaluation serves two purposes. First, it has a high sensitivity for demonstrating 
abnormalities in patients with neurosarcoidosis, even if they are relatively nonspecific. In 
addition, spinal fluid studies may be sent to help rule out other mimicking conditions of this 
disorder, such as infectious and malignant causes. 
Neurosarcoidosis reviews (Aksamit and Norona 1999, Zajicek et al 1999) offer insight into 
the details of cerebrospinal fluid findings. The cerebrospinal fluid protein is typically 
elevated in roughly 70 to 80% of patients. The value may be very highly elevated and an 
average case would be above 100.  Spinal fluid pleocytosis is seen in 55-72% of patients with 
a mean value of around 50, but values of several hundred can be seen. This is typically a 
lymphocytosis. Oligoclonal bands are positive in around 20% of patients. An elevated 
protein typically accompanies this, which might lead one to consideration of sarcoidosis, 
rather than a more typical multiple sclerosis case. Cerebrospinal fluid ACE levels are 
positive in only about 1/4 to 1/3 of patients. This low sensitivity is also coupled with 
concerns of specificity. Five of nine elevated cerebrospinal fluid ACE levels in the Mayo 
Clinic review were related to infectious or carcinomatous meningitis (Aksamit and Norona 
1999).  
Serum ACE levels have a relatively high sensitivity for undiagnosed sarcoidosis patients in 
general, and may approach 75% (Studdy and Bird 1989). Observations for patients 
presenting with neurosarcoidosis demonstrate potentially lower sensitivities overall with 
Joseph and Scolding (2009) having data of only a 29% positivity rate. This is likely due to 
many patients having a more localized expression of sarcoidosis in the nervous system.  In 
addition, this test also suffers from specificity limitations with false positives in 2-4% of 
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normals and high false positive rates in patients with infection, liver disease, renal disease, 
hyperthyroidism, Gaucher’s, and some cases of other disorders (Wallach 2000). 
Around 90% of sarcoidosis patients have pulmonary involvement (Baughman 2004); 
nevertheless, due to the potentially more isolated disease of neurosarcoidosis, those 
numbers are not as high in series of patients presenting with neurological complications.  
Regardless, 50-60% of patients still had abnormalities and so this is still a very useful 
screening method in patients with a possible diagnosis of neurosarcoidosis (Pawate et al 
2009, Joseph and Scolding 2009). Chest CT can enhance the sensitivity of pertinent findings, 
though in Pawate’s series, only two patients with a normal chest x-ray had chest CT 
findings. This demonstrated that even a routine chest x-ray is a very useful initial screening 
measure (Pawate et al 2009). Gallium scanning can demonstrate characteristic uptake 
patterns in sarcoidosis, including the lung and parotid regions, for example, and 
informative abnormalities appear to be present in roughly half of patients presenting with 
neurosarcoidosis (Zajicek et al 1999, Joseph and Scolding 2009).  
Taking into account all of the diagnostic information noted above, the main purpose is to 
guide the decision of whether to obtain a biopsy for suspicion of neurosarcoidosis, as well as 
to rule out other mimicking conditions. This confirmatory strategy is necessary in order to 
proceed with aggressive immunomodulatory medication.  If there is evidence of systemic 
disease, then biopsy of the appropriate lung (transbronchial), skin, or lymph node tissue 
would be an appropriate strategy (Aksamit and Norana 1999, Aksamit 2008, Pawate et al 
2009). In patients without this possibility, biopsy of a clinically relevant nervous system 
lesion, such as an enhancing area of the meninges or accessible significant parenchymal 
lesion could be considered for a definitive diagnosis (Aksamit 2008). Peripheral nervous 
system involvement could be biopsied, as well, with symptomatology and exam findings 
helping to guide that decision. A muscle biopsy could be considered even in patients 
without muscle related symptoms as 50% of patients have abnormalities on a muscle biopsy, 
which is well above the clinical incidence of muscle involvement (Delaney 1977). Other 
biopsy approaches of “clinically silent” areas would include a bone marrow biopsy or a 
conjunctival biopsy, which have a 30-40% chance of a positive result (Aksamit and Norona 
1999).  A conjunctival biopsy was recommended as an initial strategy by Aksamit due to its 
relatively non-invasive nature and question of whether the yield of muscle biopsy is as high 
as mentioned above (Aksamit 2008). 
4. Treatment 
Neurological involvement of sarcoidosis is, by definition, an indication for the initiation of 
medical treatment (Hunninghake et al 1999). The first line therapy is oral corticosteroids 
(Selroos 1994). For neurological disease, prednisone is to be started at around 1 mg per 
kilogram per day and continued for 6-8 weeks of high-dose therapy before beginning a 
very slow taper (Hoitsma et al 2004). Overall, treatment is suggested for last at least 6-12 
months to help avoid progression or relapse of the disease (Aksamit 2008).  Exceptions to 
this could include more benign or monophasic expressions of neurosarcoidosis, such as 
isolated Bell’s palsy or aseptic meningitis, potentially being treated on the order of weeks 
rather than more chronically, given the favorable prognosis (Luke et al 1987).  Along those 
lines the general rule is central nervous system disease, especially with significant 
parenchymal involvement or seizure activity, is more likely to have a poor prognosis and 
require more aggressive treatment than peripheral nervous system disease (Ferriby et al 
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2001, Stern et al 1985, Luke et al 1987, Scott 1993, Zajicek et al 1999). With more significant 
disease, not only is at least 6-12 months of corticosteroid treatment indicated, but steroid 
sparing agents may be necessary in cases that appear more likely to run a refractory 
course during the steroid taper or if the patient is not tolerating steroid treatment.  Some 
options include methotrexate, cyclosporin, azathioprine, cellcept, or cytoxan (Androdias 
et al 2011, Agbogu et al 1995, Stern et al 1992, Soriano et al 1990, Elkin and Willcox 1985). 
These medications will likely need to be continued for 6-12 months or longer with 
significant disease. With severe disease onset, a pulse of IV methylprednisolone for 5 days 
before starting oral corticosteroids might be necessary, and, in addition, a steroid sparing 
agent might need to be started early in the course of therapy (Scott et al 2007).  
Management of corticosteroids and the immunosuppressants outlined above should be 
undertaken by a clinician who is familiar with these medications and their practice.  
Further details of the dosing and possible toxicity are similar to the general treatment 
principles with systemic disease. Finally, hydroxychloroquine is a medication that inhibits 
antigen presentation to MHC peptide complexes and their transport to the cell surface 
(Moller 2003). This medication theoretically could be considered as an add-on medication 
with an additional mechanism of action to treat sarcoidosis, but does not have much 
efficacy in the primary treatment of neurosarcoidosis.  It may be beneficial in helping to 
maintain longer remissions in patients who have difficulty maintaining steroid remission 
without a relapse (Aksamit 2008).  It is a well tolerated medication, though monitoring for 
retinal toxicity is necessary (Baughman and Lynch 2003). Finally, radiation therapy has 
been utilized in patients refractory to all medication therapy as a last resort (Bruns et al 
2004, Menninger et al 2003).  
Unfortunately, despite the treatment approach outlined above, patients with 
neurosarcoidosis can be steroid resistant and another 20-40% of those further resistant to the 
use of conventional immunosuppressive agents (Hoitsma et al 2004). The rationale for 
utilizing these treatments is to generically suppress the inflammatory response generated by 
a TH 1 mediated reaction to the antigen stimulus of sarcoidosis.  The TH 1 mediated 
response to MHC-II complexes formed from antigen stimuli in sarcoidosis heavily involves 
interleukin-2, interleukin-12, interferon-γ, and tumor necrosis factor-α (Moller 2003). Tumor 
necrosis factor-α is the main cytokine of interest, and there have been several clinical trials 
of direct therapy to block it with encouraging results. The predominant examples of this 
include infliximab and thalidomide.  Infliximab is a monoclonal antibody that blocks tumor 
necrosis factor-α. Concerns of infection related to immunosuppression, cytopenias, a 
paradoxical provocation of multiple sclerosis, allergic reactions, and significant cost of the 
medication are all factors that could limit its use.  Nevertheless, there is a large and growing 
support for its efficacy, though lacking any confirmatory prospective study.  Its use may be 
considered in patients refractory to other medical treatment (Pereira et al 2011, Santos et al 
2010, Aksamit 2008).  Likewise, thalidomide also has properties that involve tumor necrosis 
factor-α blockade. This medication is most known for its concerns for teratogenic effects, 
such as phocomelia, and it now has to be prescribed through the system for thalidomide 
education and prescribed safety (STEPS), only available to be prescribed through select 
physicians.  In addition, toxicity such as an axonal sensory polyneuropathy develops in 
about 20% of patients.  Sedation is the main limitation of the medication otherwise, which is 
very slowly titrated as tolerated from 100 mg to a max of 800 mg as needed (though 
typically 400 mg or less for maintenance). Other side effects could include rash, 
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thromboembolism, dizziness, and constipation. (Wu et al 2005)  In contrast to other 
immunosuppressive therapies, there is not a significantly increased risk of infection with 
patients on thalidomide (Baughman and Lower 2004).  Our experience is consistent with 
other authors, and demonstrates the efficacy of thalidomide in patients with steroid and 
immunosuppressant-refractory neurosarcoidosis (Hoyle, Newton, Katz 2008, Hammond et 
al 2007, Nguyen et al 2004).  
The future trends in therapy will likely involve the use of drugs targeted to the 
underlying pathophysiology of sarcoidosis, such as the new tumor necrosis factor-α 
inhibitors currently under investigation. Also, future prevention or possible treatment of 
neurosarcoidosis could be enhanced by a better understanding of the antigen responsible 
for initiating sarcoidosis, and why such a small percentage of patients develop 
neurological involvement. Proprionibacterium and mycobacterium have been two 
antigenic candidates that have not resulted in any significant disease modification with 
attempts at treatment. Other environmental antigens have been proposed, as well.  
Further exploration of the antigenic source of initiation of sarcoidosis, the conditions that 
allow the host response to become susceptible to the development of non-caseating 
granulomas and, more specifically, how this can selectively occur in the nervous system 
will hopefully yield progress in the field.  
5. Conclusion 
Neurosarcoidosis is a complex disorder that may involve virtually any aspect of the 
nervous system.  Nevertheless, it may present with certain classical features, such as 
cranial nerve involvement, meningeal based disease, or hypothalamic-pituitary axis 
symptomatology to alert one to the possibility of this diagnosis.  Seizures, spinal cord 
involvement, encephalopathy/psychiatric symptomatology, and peripheral neuropathy 
occur with intermediate frequencies and less specificity for suspecting this condition, but 
need to be understood in the context of other clues systemically or otherwise to the 
disorder. 
Diagnosis in cases of known systemic sarcoidosis is more straightforward, but in the 
absence of systemic features on presentation, diagnosis may be complicated.  MRI of the 
brain with contrast (and potentially spinal cord) and cerebrospinal fluid studies are 
mandatory in the initial evaluation to not only demonstrate features suggesting a need to 
pursue a pathological tissue diagnosis, but also important in evaluating for other 
mimickers of the disease, chief among those being infection or malignancy. ACE levels 
have relatively poor sensitivity and specificity, but can increase suspicion of the disorder 
in cases without other apparent clues. A detailed clinical understanding of the features of 
systemic disease is important background knowledge for evaluating patients with 
potential neurosarcoidosis. Routine chest imaging and potentially gallium studies if 
needed can be helpful noninvasive adjuncts. Nevertheless, tissue diagnosis remains the 
gold standard and is necessary before committing to significant immunomodulatory 
therapy. 
Corticosteroids remain the first-line therapy of neurosarcoidosis with steroid sparing agents 
reserved for more severe or refractory disease, or for patients who are intolerant to 
corticosteroids.  Selective therapy of downstream inflammatory features of sarcoidosis, such 
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as with tumor necrosis factor-α antagonists, are becoming more recognized as options in 
refractory disease. Further exploration of targeted immunomodulatory therapy, better 
understanding of the antigenic initiation of the disease, and discovery of host factors that 
make one susceptible not only to sarcoidosis, but specifically nervous system involvement, 
are important areas for future progress in treating this disorder.  
6. References 
Agbogu BN, Stern BJ, Sewell C, Yang G. Arch Neurol. Therapeutic considerations in 
patients with refractory neurosarcoidosis. 1995 Sep;52(9):875-9. 
Aksamit AJ, Norona F.  Neurosarcoidosis without systemic sarcoid. Ann Neurol 
1999;46:471. 
Aksamit.  Neurosarcoidosis. Continuum.  2008;14(1):181-196.  
Alon EE, Ekbom DC.  Neurosarcoidosis affecting the vagus nerve. Ann Otol Rhinol 
Laryngol. 2010 Sep;119(9):641-5.  
Androdias G, Maillet D, Marignier R, Pinède L, Confavreux C, Broussolle C, Vukusic S, Sève 
P. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid 
myopathy.Neurology. 2011 Mar 29;76(13):1168-72. 
Armin A, Balderacchi JL. Trigeminal neurosarcoidosis: case report and literature review. Ear 
Nose Throat J. 2010 Jul;89(7):320-2. 
Aubart FC, Quayoun M, Brauner M, Attali P, Kambouchner M, Valeyre D, Nunes H. 
Sinonasal involvement in sarcoidosis: a case-control study of 20 patients.  2006 
Nov;85(6):365-71. 
Baughman RP.  Pulmonary sarcoidosis.  Clin Chest Med. 2004;25(3):521. 
Baughman RP, Lower EE: Newer therapies for cutaneous sarcoidosis – the role of 
thalidomide and other agents. Am J Clin Derm 2004, 5(6):385-94.  
Baughman RP, Lynch JP.  Difficult treatment issues in sarcoidosis.  Journal of Internal 
Medicine.  2003;253;41-45. 
Bona JR, Fackler SM, Fendley MJ, Nemeroff CB. Neurosarcoidosis as a cause of refractory 
psychosis: a complicated case report. Am J Psychiatry. 1998 Aug; 155 (8): 1106 -8.  
Bruns F, Pruemer B, Haverkamp U, Fischedick AR. Neurosarcoidosis: an unusual indication 
for radiotherapy.  Br J Radiol 2004 Sep; 77(921):777-9. 
Burns TM, Dyck PJ, Aksamit AJ, Dyck PJ. The natural history and long-term outcome of 57 
limb sarcoidosis neuropathy cases. J Neurol Sci. 2006 May 15; 244 (1-2):77-87. 
Chapelon C, Ziza JM, Piette JC, et al. Neurosarcoidosis: signs course and treatment in 35 
confirmed cases. Medicine 1990;69:261-76 
Christoforidis GA, Spickler EM, Reccio MV, Mehta BM. MR of CNS sarcoidosis: correlation 
of imaging features to clinical symptoms and response to treatment. AJNR1999; 
20:655 –669 
Colover J. Sarcoidosis with involvement of the nervous system. Brain 1948; 71:451-75. 
De Mulder D, Vandenberghe J. Neurosarcoidosis as a cause of manic psychosis.Tijdschr 
Psychiatr. 2008;50(11):741-5. Dutch.  
Delaney P. Neurologic manifestations in sarcoidosis: review of literature, with a report of 23 
cases. Ann Intern Med 1977;87(3):336-45. 
www.intechopen.com
 
Sarcoidosis Diagnosis and Management 
 
236 
Elkin R, Willcox PA. Neurosarcoidosis. A report of 5 cases. S Afr Med J. 1985 Jun 
8;67(23):943-6. 
Fahoum F, Drory VE, Issakov J, Neufeld MY.  Neurosarcoidosis presenting as Guillain-Barre 
like syndrome. A case report and review of the literature. J Clin Neuromuscul Dis. 
2009 Sep;11(1):35-43. 
Ferriby D, de Seze J, Stojkovic, T, Hachulla E, Wallaert B, Destee A, Hatron PY, Vermersch P.  
Long-term follow-up of neurosarcoidosis.  Neurology 2001;57;927-929. 
Friedman SH, Gould DJ. Neurosarcoidosis presenting as psychosis and dementia: a case 
report.Int J Psychiatry Med. 2002;32(4):401-3. 
Garg S, Wright A, Reichwein R, Boyer P, Towfighi J, Kothari MJ. Mononeuritis multiplex 
secondary to sarcoidosis.Clin Neurol Neurosurg. 2005 Feb;107(2):140-3. 
Gilmore K, Rudden M, Kalman TP. Psychiatric manifestations of sarcoidosis. Can J 
Psychiatry 1980;25:329-31. 
Hammond ER, Kaplin AI, Kerr DA. Thalidomide for acute treatment of neurosarcoidosis. 
Spinal Cord 2007;45(12):802-3. 
Heerfordt CF. Uber eine "Febris uveo-parotidea subchronica" an der glandula parotis und 
der uvea des anges lokalisiert und haufig mit paresen cerebrospinaler nerven 
kompliaiert. V Graef Arch Klin Exp Ophthalmol 1909;70:254.  
Hoitsma E, Faber CG, Drent M, Sharma OP: Neurosarcoidosis: a clinical dilemma. Lancet 
Neurol 2004, 3(7):397-407. 
Hoitsma E, Marziniak M, Faber GC, Reulen JP, Sommer C, De Baets M, Drent M.  Small fibre 
neuropathy in sarcoidosis.  Lancet 359 (2002), pp 2085-2086. 
Hoyle JC, Newton HB, Katz S.  Prognosis of refractory neurosarcoidosis altered by 
thalidomide: a case report.  Journal of Medical Case Reports 2008, 2:27 
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, 
Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP: 
ATS/ERS/WASOG Statement Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999, 
16:149-173.  
Joseph FG, Scolding NJ.  Neurosarcoidosis: A study of 30 new cases. Neurol Neurosurg 
Psychiatry 2009 Mar;80(3):297-304.  
Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol 2007;7:234-244. 
Junger SS, Stern BJ, Levine SR, Sipos E, Marti-Masso JF.  Intramedullary spinal sarcoidosis:  
Clinical and magnetic resonance imaging characteristics.  Neurology 1993; 43: 333-
337. 
Luke RA, Stern BJ, Krumholz A, Johns CJ.  Neurosarcoidosis: the long-term clinical course.  
Neurology 1987 Mar;37(3):461-3. 
Menninger MD, Amdur RJ, Marcus RB Jr.  Am J Clin Oncol 2003 Aug;26(4):e115-8. 
Moller DR: Treatment of sarcoidosis – from a basic science point of view. Journal of Internal 
Medicine 2003, 253:31-40.  
Nguyen YT, Dupuy A, Cordoliani F, Vignon-Pennamen MD, Lebbe C, Morel, P, Rybojad M.  
Treatment of cutaneous sarcoidosis with thalidomide.  J Am Acad Dermatol 
2004;50:235-241. 
Niemer GW, Bolster MB, Buxbaum L, Judson MA.  Carpal tunnel syndrome in sarcoidosis. 
Sarcoidosis Vasc Diffuse Lung Dis. 2001;18(3):296. 
www.intechopen.com
 
Neurological Sarcoidosis 
 
237 
O'Brien GM, Baughman RP, Broderick JP, Arnold L, Lower EE. Paranoid psychosis due to 
neurosarcoidosis. Sarcoidosis. 1994 Mar;11(1):34-6. 
Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Med 
Scand 1986;73:283-90. 
Pawate S, Moses H, Sriram S.  Presentations and outcomes of neurosarcoidosis: a study of 54 
cases.QJM. 2009 Jul;102(7):449-60.  
Pereira J, Anderson NE, McAuley D, Bergin P, Kilfoyle D, Fink J.  Medically refractory 
neurosarcoidosis treated with infliximab.  Intern Med J 2011 Apr;41(4):354-7. 
Porter N, Beynon HL, Randeva HS.  Endocrine and reproductive manifestations of 
sarcoidosis.  QJM. 2003 Aug;96(8):553-61.  
Sabaawi M, Gutierrez-Nunez J, Fragala MR. Neurosarcoidosis presenting as 
schizophreniform disorder. Int J Psychiatry Med. 1992;22(3):269-74. 
Santos E, Shaunak S, Renowden S, Scolding NJ.  Treatment of refractory neurosarcoidosis 
with infliximab.  J Neurol Neurosurg Psychiatry.  2010 Mar;81(3):241-6. 
Scott, TF.  Neurosarcoidosis: Progress and clinical aspects.  Neurology 1993;43:8-12. 
Scott TF, Yandora K, Valeri A, Chieffe C, Schramke C.  Aggressive therapy for 
neurosarcoidosis: long-term follow-up of 48 treated patients.  Arch Neurol. 
2007;64(5):691. 
Selroos O.  Treatment of sarcoidosis.  Sarcoidosis 1994;11:80-83. 
Sierra-Hidalgo F, Moreno-Ramos T, Martinez de Aragon A, Correas-Callero E, Erana I, de 
Pablo-Fernandez E. Longitudinal myelitis as the presenting symptom of 
neurosarcoidosis.  Rev Neurol 2010 Sep 1;51(5):302. 
Soriano FG, Caramelli P, Nitrini R, Rocha AS. Neurosarcoidosis: therapeutic success with 
methotrexate. Postgrad Med J. 1990 Feb;66(772):142-3. 
Spiegel DR, Thomas CS, Shah P, Kent KD.  A possible case of mixed mania due to 
neurosarcoidosis treated successfully with methylprednisolone and ziprasidone: 
another example of frontal-subcortical disinhibition?Gen Hosp Psychiatry. 2010 
May-Jun;32(3):342. 
Stern BJ, Krumholz A, Johns C, Scott P, Nissim J.  Sarcoidosis and its neurological 
manifestations.  Arch Neurol. 1985 Sep;42(9):909-17. Review. 
Stern BJ, Schonfeld SA, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of 
neurosarcoidosis with cyclosporine. Arch Neurol. 1992 Oct;49(10):1065-72. 
Stuart C, Neelon F, Lebovitz H. Disordered control of thirst in hypothalamic-pituitary 
sarcoidosis. N Engl J Med 1980; 303:1078–82. 
Studdy PR, Bird R.  Serum angiotensin converting enzyme in sarcoidosis--its value in 
present clinical practice.  Ann Clin Biochem. 1989;26 ( Pt 1):13. 
Tavee J, Culver D. Sarcoidosis and small fiber neuropathy. Curr Pain Headache Rep 2011 
June;15(3):201-6. 
Turkington RW, MacIndoe JH. Hyperprolactinemia in sarcoidosis. Ann Intern Med 
1972;76(4):545-9. 
Wallach J. Interpretation of Diagnostic Tests, 7th Ed., 2000. 
Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK: Thalidomide: dermatological indications, 
mechanisms of action and side-effects. British Journal of Dermatology 2005, 
153:254-73. 
www.intechopen.com
 
Sarcoidosis Diagnosis and Management 
 
238 
Zajicek JP, Scolding NJ, Foster O, et al.  Central nervous system sarcoidosis-diagnosis and 
management.  QJM 1999;92(2):103-117. 
Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology. 1991;41(10):1558. 
www.intechopen.com
Sarcoidosis Diagnosis and Management
Edited by Prof. Mohammad Hosein Kalantar Motamedi
ISBN 978-953-307-414-6
Hard cover, 280 pages
Publisher InTech
Published online 17, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Sarcoidosis is a type of inflammation that occurs in various locations of the body for no known reason.
Normally, when foreign substances or organisms enter the body, the immune system will fight back by
activating an immune response. Inflammation is a normal part of this immune response, but it should subside
once the foreign antigen is gone. In sarcoidosis, the inflammation persists, and some of the immune cells form
abnormal clumps of tissue called granulomas. The disease can affect any organ in the body, but it is most
likely to occur in the lungs. It can also affect the skin, eyes, liver, or lymph nodes. Although the cause of
sarcoidosis is not known, research suggests that it may be due to an extreme immune response or extreme
sensitivity to certain substances. It also seems to have a genetic component as well, and tends to run in
families. Sarcoidosis most commonly develops in people between 20 and 50 years of age. African Americans
are somewhat more likely to develop sarcoidosis than Caucasians, and females are somewhat more likely to
develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
J. Chad Hoyle and Herbert B. Newton (2011). Neurological Sarcoidosis, Sarcoidosis Diagnosis and
Management, Prof. Mohammad Hosein Kalantar Motamedi (Ed.), ISBN: 978-953-307-414-6, InTech, Available
from: http://www.intechopen.com/books/sarcoidosis-diagnosis-and-management/neurological-sarcoidosis
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
